Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23NO2.ClH |
Molecular Weight | 345.863 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(COC(O1)(C2=CC=CC=C2)C3=CC=CC=C3)[C@]4([H])CCCCN4
InChI
InChIKey=GYPWNVSWCIMIHQ-GRTNUQQKSA-N
InChI=1S/C20H23NO2.ClH/c1-3-9-16(10-4-1)20(17-11-5-2-6-12-17)22-15-19(23-20)18-13-7-8-14-21-18;/h1-6,9-12,18-19,21H,7-8,13-15H2;1H/t18-,19+;/m0./s1
Molecular Formula | C20H23NO2 |
Molecular Weight | 309.4021 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Dexoxadrol is a sigma receptor agonist. Dexoxadrol, the D-isomer of dioxodrol, which produces PCP-like behavioural effects and displaces bound [3H]PCP, was a potent blocker of the PCP-sensitive, voltage-gated K+ channel. Dexoxadrol was developed as analgesics for use in humans, however, severe side effects including psychotomimetic effects, unpleasant dreams and aberrations stopped the clinical evaluation of dexoxadrol. Dexoxadrol is a NMDA receptor antagonist, which possesses high affinity to the phencyclidine binding site within the NMDA receptor associated ion channel.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907608 |
104.0 nM [Ki] | ||
Target ID: CHEMBL1907604 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26430967 |
19.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 74 Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 74 Sources: |
Other AEs: psychosis... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
psychosis | 5 patients | 20 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 74 Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 74 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode. | 2002 Feb |
|
Structure-affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol. | 2005 Dec 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16719812
In hospitalized cancer and arthritic patients dexoxadrol at 10 mg or 20 mg dosage in combination
with 600 mg of acetylsalicylic acid has analgesic
properties significantly superior to either acetylsalicylic acid
(600 mg) or codeine (60 mg) alone. Administration of dexoxadrol (20 mg, orally, twice daily) to
128 patients with severe pain gave complete relief to 50 %
and partial relief to 28 % of the patients.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3038243
Dexoxadrol (10 uM) selectively blocked the secondary components of the synaptic response in rat hippocampal slices.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:50 GMT 2023
by
admin
on
Fri Dec 15 15:25:50 GMT 2023
|
Record UNII |
T0C1IR71L8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
631-06-1
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL72982
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
1162-15-8
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
SUPERSEDED | |||
|
C005840
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
T0C1IR71L8
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
C77324
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
71658
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | |||
|
m4597
Created by
admin on Fri Dec 15 15:25:50 GMT 2023 , Edited by admin on Fri Dec 15 15:25:50 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |